These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 28652891)

  • 41. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.
    Pacifico L; Nobili V; Anania C; Verdecchia P; Chiesa C
    World J Gastroenterol; 2011 Jul; 17(26):3082-91. PubMed ID: 21912450
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Non-alcoholic fatty liver].
    Tagle Arrospide M
    Rev Gastroenterol Peru; 2003; 23(1):49-57. PubMed ID: 12768215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.
    Scapaticci S; D'Adamo E; Mohn A; Chiarelli F; Giannini C
    Front Endocrinol (Lausanne); 2021; 12():639548. PubMed ID: 33889132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
    Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
    Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological features of non-alcoholic fatty liver disease.
    Sugimoto K; Takei Y
    Hepatol Res; 2011 Oct; 41(10):911-20. PubMed ID: 21951869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis.
    Sakuma T; Nakamura M; Chiba T; Iwanaga T; Kan M; Kojima R; Ao J; Ma Y; Unozawa H; Fujita N; Kanayama K; Kanzaki H; Koroki K; Kobayashi K; Nakagawa R; Kanogawa N; Kiyono S; Kondo T; Saito T; Ogasawara S; Nakamoto S; Muroyama R; Kato J; Kishimoto T; Kato N
    Lab Invest; 2022 Oct; 102(10):1150-1157. PubMed ID: 35643859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucocorticoids and non-alcoholic fatty liver disease.
    Woods CP; Hazlehurst JM; Tomlinson JW
    J Steroid Biochem Mol Biol; 2015 Nov; 154():94-103. PubMed ID: 26241028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comorbidities and Metabolic Derangement of NAFLD.
    Bang KB; Cho YK
    J Lifestyle Med; 2015 Mar; 5(1):7-13. PubMed ID: 26528424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
    Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A
    Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
    Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
    Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum.
    Fitzpatrick E
    Proc Nutr Soc; 2019 Aug; 78(3):362-371. PubMed ID: 30732664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Not Available].
    Buffet C
    Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.